| Assessment Status |
Rapid Review Complete |
| HTA ID |
24048 |
| Drug |
Cemiplimab |
| Brand |
Libtayo® |
| Indication |
Cemiplimab (Libtayo®) is indicated as monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy. |
| Rapid review commissioned |
02/12/2024 |
| Rapid review completed |
17/01/2025 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of cemiplimab for this indication compared with the current standard of care. |
